Trial Profile
Randomised double blinded placebo controlled trial to assess the effect of oral nicotinamide on numbers of new nonmelanoma skin cancers in immune suppressed adult renal transplant recipients with a history of at least two histologically confirmed nonmelanoma skin cancers within the previous 12 months
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Nicotinamide (Primary)
- Indications Skin cancer
- Focus Therapeutic Use
- 18 Jun 2012 New trial record
- 14 Jun 2012 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.